Stent Thrombosis: a note of caution Dr. Conrad Simpfendorfer
Arteriosclerosis, Thrombosis and Vascular Biology
Arteriosclerosis, Thrombosis and Vascular Biology.
PROTECT: A comparison of thrombosis incidence between the drug-eluting stents sirolimus and zotarolimus.
Summary: Randomized, open, pragmatic essay PROTECT (patient related outcomes of Endeavor versus Cypher stenting trial) compared two drug-eluting stents with different behaviors, (Cypher ® and Endeavor ®), in the reendothelialization degree and antiproliferative potency. Cypher has a permanent sirolimus-eluting polymer which generates a potent antiproliferative effect and a suboptimal healing (or reendothelialization). Furthermore, Endeavor has<a href="https://solaci.org/en/2015/06/24/protect-a-comparison-of-thrombosis-incidence-between-the-drug-eluting-stents-sirolimus-and-zotarolimus/" title="Read more" >...</a>
Contemporary Strategies for the Prevention and Management of Stent Thrombosis
Julio Lopez Cuellar 2012-08-08
Lower Rates of In-Stent Thrombosis with the New Generation DES
Original title: New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL registry. Reference: Vignali L et al. Cath Cardiovasc Interv. 2014; Epub ahead of print. Compared to the first generation of drug eluting stents (DES), the new generation has a lower long term risk of in-stent thrombosis and acute myocardial infarction<a href="https://solaci.org/en/2014/10/30/lower-rates-of-in-stent-thrombosis-with-the-new-generation-des/" title="Read more" >...</a>
Resistance to Aspirin Associated to Greater Risk of In-Stent Thrombosis and Death
Original title: Aspirin Treatment and Outcomes After Percutaneous Coronary InterventionResults of the ISAR-ASPI Registry. Reference: Katharina Mayer et al. J Am CollCardiol. 2014;64(9):863-871. Aspirin administration, as part of the double antiagregation scheme, is essential in the context of PCI. The correlation between high platelet reactivity to on-clopidogrel treatment and higher events rates has been well established, while data<a href="https://solaci.org/en/2014/08/29/resistance-to-aspirin-associated-to-greater-risk-of-in-stent-thrombosis-and-death/" title="Read more" >...</a>
Less Definite Thrombosis with Everolimus Eluting Stents
Original title: Three-Year Outcomes After Revascularization With Everolimus-and Sirulimus -Eluting Stents From the SORT OUT IV Trial. Reference: Lisette Okkels Jensen et al. J Am CollCardiolIntv, 2014;7: 840-8. Drug eluting stents (DES) have been shown to safely and effectively reduce restenosis compared to bare-metal stents. While the risk of thrombosis remains a matter of concern when it comes<a href="https://solaci.org/en/2014/08/29/less-definite-thrombosis-with-everolimus-eluting-stents/" title="Read more" >...</a>
Less Bleeding at the Expense of a Higher Risk of Acute Thrombosis with Bivalirudin
Original title: Bivalirudin versus heparin in patients treated with percutaneous coronary Intervention: a meta-analysis of randomised trials. Reference: Salvatore Cassese et al. EuroIntervention 2014;10-online publish-ahead-of-print August 2014. Current recommendations for the use of bivalirudin in PCI patients are mostly based on studies comparing bivalirudin vs. heparin combined with glycoprotein IIb/IIIa inhibitors. Whether bivalirudin is superior to heparin alone<a href="https://solaci.org/en/2014/08/20/less-bleeding-at-the-expense-of-a-higher-risk-of-acute-thrombosis-with-bivalirudin/" title="Read more" >...</a>